Key statistics
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | 111.15 |
Low | 111.15 |
Bid | -- |
Offer | -- |
Previous close | 111.15 |
Average volume | -- |
---|---|
Shares outstanding | 1.63bn |
Free float | 1.52bn |
P/E (TTM) | -- |
Market cap | 68.75bn HKD |
EPS (TTM) | -0.8837 HKD |
Data delayed at least 20 minutes, as of Jul 16 2024.
More ▼
Press releases
- Innovent Announces Clinical Data of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) Combined with Bevacizumab in Advanced Colorectal Cancer at the 2024 ESMO Congress
- Innovent Delivers Oral Presentations on Clinical Data of IBI354 (HER2 Monoclonal Antibody-Camptothecin Derivative Conjugate) in Advanced Ovarian Cancer, Breast Cancer and Other Solid Tumors at the 2024 ESMO Congress
- Head-to-head Superiority over Dulaglutide: Innovent's Phase 3 Clinical Trial DREAMS-2 of Mazdutide in Chinese Patients with Type 2 Diabetes were Orally Presented at EASD 2024
- Innovent Delivers Oral Presentation on Phase 1 Clinical Data of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Advanced Non-small Cell Lung Cancer at the 2024 WCLC
- Innovent Delivers Oral Presentation of Updated Results from a Pivotal Phase 2 Study of Dupert® (Fulzerasib) in Patients with Advanced Non-Small Cell Lung Cancer Harboring KRAS G12C Mutation
- Innovent Receives Fast Track Designation from the U.S. FDA for IBI363 (PD-1/IL-2α Bispecific Antibody Fusion Protein) as Monotherapy for Advanced Melanoma
- Innovent Annouces Multiple Clinical Study Results of Mazdutide to be Presented at the EASD 2024
- Innovent to Present Clinical Data of Multiple Novel Molecules at WCLC and ESMO 2024
- Innovent Announces 2024 Interim Results and Business Updates
- China's First Approved KRAS G12C Inhibitor: Innovent Announces the Approval of Dupert® (Fulzerasib) by the National Medical Products Administration of China
More ▼